RNA medicines can treat some diseases by hitting targets otherwise considered “undruggable” by small molecules and biologics, but protecting the nucleic acids from degradation and getting the therapies to where they are needed in the body can be difficult.
San Diego startup DTx Pharma has raised $10.6 million to advance technology it has developed that uses fatty acids in an effort to overcome delivery and distribution issues. The sum includes an undisclosed amount from Eli Lilly (NYSE: LLY), which has made a number of investments in biotechs pursuing RNA-focused technologies.
DTx, which is based at the Johnson & Johnson (NYSE:… Read more »
UNDERWRITERS AND PARTNERS
